Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

18.2%

2 terminated/withdrawn out of 11 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT06860555Completed

Hyperspectral Drusen Classification

Role: lead

NCT06860568Completed

The GA in HSI Study

Role: lead

NCT06161636Recruiting

Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's Disease

Role: collaborator

NCT05903651Completed

Retinal Deep PhenotypingTM

Role: lead

NCT05107882Completed

Optina Diagnostics' Cerebral ß-Amyloid Status (CAS) Test

Role: lead

NCT05199428Completed

Optina Eye to Heart Connection

Role: lead

NCT06057493Completed

RDP Reliability Study

Role: lead

NCT05903664Withdrawn

Retinal Deep Phenotyping.TM

Role: lead

NCT03420807Not ApplicableCompleted

Retinal Metabolic Imaging of Alzheimer Patient

Role: lead

NCT03442816Not ApplicableWithdrawn

Retinal Metabolic Imaging in a Diverse Population

Role: lead

NCT05215782Completed

Eye to Brain Connection

Role: lead

All 11 trials loaded